Overview

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

Status:
RECRUITING

Trial end date:
2029-11-30

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control high-risk hematological malignancies in patients who need a second allogeneic stem cell transplantation.

Phase:

PHASE2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

fludarabine
Mycophenolic Acid
Tacrolimus
Thiotepa